文拉法辛或安非他酮药物相互作用下仍可通过多巴胺转运体SPECT可靠诊断黑质纹状体退变
本研究回顾性纳入43例在文拉法辛、安非他酮或两者联用下接受[123I]FP-CIT-SPECT的患者,将纹状体特异性结合比(SBR)、左右不对称性及壳核/尾状核比转为z分数后行聚类分析,识别出两类模式;随访临床参考诊断为神经退行性(n=8)与非神经退行性(n=16)帕金森综合征的患者分别仅归入前一类与后一类(p<0.001)。结论认为文拉法辛与安非他酮引起纹状体[123I]FP-CIT SBR的均匀性降低,可与帕金森病样降低相区分。
要点
- 文拉法辛和安非他酮引起纹状体[123I]FP-CIT SBR均匀性降低,可与帕金森病样降低相区分。
- 聚类分析识别两类模式:帕金森病样模式与对称性降低但纹状体内梯度正常模式。
- 随访诊断为神经退行性与非神经退行性帕金森综合征者分别仅归入前一类与后一类(p<0.001)。
核心结论
- 文拉法辛和安非他酮引起纹状体[123I]FP-CIT SBR均匀性降低,该降低可与帕金森病样降低相区分。
研究设计与样本
- 回顾性纳入43例患者(70.7 ± 8.6岁,44%为女性),在文拉法辛(n=26,37.5-225 mg/d)、安非他酮(n=16,150或300 mg/d)或两者联用(n=1)下接受[123I]FP-CIT-SPECT。
- 将纹状体特异性[123I]FP-CIT结合比(SBR)、其左右不对称性及壳核/尾状核比转换为z分数后行聚类分析,进行数据驱动分类。
主要发现
- 识别出两个聚类:第一聚类(37%病例)呈帕金森病样模式,纹状体SBR/不对称性/壳核/尾状核z分数中位数分别为-4.5/4.9/-3.8。
- 第二聚类(63%病例)呈对称性降低且纹状体内梯度正常,纹状体SBR/不对称性/壳核/尾状核z分数中位数分别为-2.7/0.4/0.2。
- 随访临床参考诊断为神经退行性帕金森综合征(n=8)与非神经退行性帕金森综合征(n=16)的患者分别仅归入第一聚类与第二聚类(p<0.001)。
关键数值与推荐
- 第一聚类(37%病例)纹状体SBR/不对称性/壳核/尾状核z分数中位数为-4.5/4.9/-3.8。
- 第二聚类(63%病例)纹状体SBR/不对称性/壳核/尾状核z分数中位数为-2.7/0.4/0.2。
- 神经退行性(n=8)与非神经退行性(n=16)帕金森综合征的聚类归属差异p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study examined the impact of venlafaxine and bupropion on the detection of nigrostriatal degeneration by dopamine transporter (DAT)-SPECT. METHODS: 43 patients (70.7 ± 8.6y, 44% female) with [123I]FP-CIT-SPECT under venlafaxine (n = 26, 37.5-225 mg/d), bupropion (n = 16, 150 or 300 mg/d) or both (n = 1) were included retrospectively. The striatal specific [123I]FP-CIT binding ratio (SBR), its left-right asymmetry and the putamen-to-caudate ratio were transformed to z-scores and submitted to a cluster analysis for data-driven categorization. RESULTS: Two clusters were identified. The first cluster (37% cases) showed a Parkinson's disease (PD)-like pattern: median striatal SBR/asymmetry/putamen-to-caudate z-score -4.5/4.9/-3.8. The second cluster (63%) showed symmetric reduction with normal intra-striatal gradient: median striatal SBR/asymmetry/putamen-to-caudate z-score -2.7/0.4/0.2. Patients with follow-up clinical reference diagnoses of neurodegenerative (n = 8) and non-neurodegenerative (n = 16) parkinsonism fell exclusively into the former or the latter cluster, respectively (p < 0.001). CONCLUSION: Venlafaxine and bupropion cause uniform reduction of the striatal [123I]FP-CIT SBR that can be distinguished from PD-like reductions.
引用
- Apostolova I, Hellwig S, Karimzadeh A, et al. Reliable diagnosis of nigrostriatal degeneration by dopamine transporter SPECT despite drug interaction with venlafaxine or bupropion. Eur J Nucl Med Mol Imaging. 2024. PMID: 39614909. doi:10.1007/s00259-024-06989-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。